-
公开(公告)号：US20160376276A1
公开(公告)日：2016-12-29
申请号：US15038818
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Daniel Christopher Brookings , Julien Alistair Brown , Victoria Elizabeth Jackson , John Robert Porter , Joanna Rachel Quincey
IPC: C07D487/04 , A61K31/53
CPC classification number: C07D487/04 , A61K31/53 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14
Abstract: A series of substituted imidazo[1,2-b][1,2,4]triazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人类TNFα活性的有效调节剂的一系列取代的式（I）咪唑并[1,2-b] [1,2,4]三嗪衍生物因此有益于治疗和/或预防各种人类疾病 ，包括自身免疫性和炎症性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：US09309243B2
公开(公告)日：2016-04-12
申请号：US14414287
申请日：2013-07-05
Applicant: UCB Biopharma SPRL
Inventor： Jonathan Mark Bentley , Daniel Christopher Brookings , Julien Alistair Brown , Thomas Paul Cain , Praful Tulshi Chovatia , Anne Marie Foley , Ellen Olivia Gallimore , Laura Jane Gleave , Alexander Heifetz , Helen Tracey Horsley , Martin Clive Hutchings , Victoria Elizabeth Jackson , James Andrew Johnson , Craig Johnstone , Boris Kroeplien , Fabien Claude Lecomte , Deborah Leigh , Martin Alexander Lowe , James Madden , John Robert Porter , Joanna Rachel Quincey , Laura Claire Reed , James Thomas Reuberson , Anthony John Richardson , Sarah Emily Richardson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu
IPC: C07D491/02 , C07D471/04 , C07D519/00 , A61K31/437 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/5513 , A61K31/554 , C07D491/107
CPC classification number: C07D471/04 , A61K31/437 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/5513 , A61K31/554 , C07D491/107 , C07D519/00
Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人类TNFα活性的有效调节剂的一系列式（I）的咪唑并[1,2-a]吡啶衍生物因此有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
Patent Agency Ranking
公开(公告)号：US20150274748A1
公开(公告)日：2015-10-01
申请号：US14432842
申请日：2013-10-02
Inventor： Claire Louise Kulisa , Daniel Christopher Brookings , Daniel James Ford , Richard Jeremy Franklin , James Thomas Reuberson , Anant Ramrao Ghawalkar
IPC: C07D495/04
CPC classification number: C07D495/04 , A61K31/424 , C07D413/14
Abstract: Compounds of formula (I) i.e. monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives substituted by an optionally substituted oxazolin-2-yl moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.
Abstract translation: 式（I）化合物，即被任选取代的恶唑啉-2-基部分取代的单环或双环二胺取代的噻吩并[2,3-d]嘧啶和异噻唑并[5,4-d]嘧啶衍生物在治疗中是有益的 和/或预防各种人类疾病，包括炎症，自身免疫和肿瘤疾病; 病毒性疾病 和器官和细胞移植排斥反应。
-
公开(公告)号：US09873703B2
公开(公告)日：2018-01-23
申请号：US15038733
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Mezher Hussein Ali , Daniel Christopher Brookings , Julien Alistair Brown , Martin Clive Hutchings , Victoria Elizabeth Jackson , Boris Kroeplien , John Robert Porter , Joanna Rachel Quincey
IPC: C07D487/04 , A61K31/5025 , A61K31/506 , A61K31/5377
CPC classification number: C07D487/04 , A61K31/5025 , A61K31/506 , A61K31/5377
Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09714251B2
公开(公告)日：2017-07-25
申请号：US15038818
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Daniel Christopher Brookings , Julien Alistair Brown , Victoria Elizabeth Jackson , John Robert Porter , Joanna Rachel Quincey
IPC: C07D487/04 , C07D403/04 , C07D403/12 , C07D403/14 , C07D401/04 , C07D401/12 , C07D401/14 , A61K31/53 , A61P19/02
CPC classification number: C07D487/04 , A61K31/53 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14
Abstract: A series of substituted imidazo[1,2-b][1,2,4]triazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09382263B2
公开(公告)日：2016-07-05
申请号：US14432842
申请日：2013-10-02
Inventor： Claire Louise Kulisa , Daniel Christopher Brookings , Daniel James Ford , Richard Jeremy Franklin , James Thomas Reuberson , Anant Ramrao Ghawalkar
IPC: C07D495/04 , A61K31/424 , C07D413/14
CPC classification number: C07D495/04 , A61K31/424 , C07D413/14
Abstract: Compounds of formula (I) i.e. monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives substituted by an optionally substituted oxazolin-2-yl moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.
Abstract translation: 式（I）化合物，即被任选取代的恶唑啉-2-基部分取代的单环或双环二胺取代的噻吩并[2,3-d]嘧啶和异噻唑并[5,4-d]嘧啶衍生物在治疗中是有益的 和/或预防各种人类疾病，包括炎症，自身免疫和肿瘤疾病; 病毒性疾病 和器官和细胞移植排斥反应。
-
公开(公告)号：US20150191482A1
公开(公告)日：2015-07-09
申请号：US14414299
申请日：2013-07-05
Applicant: UCB Biopharma SPRL
Inventor： Jonathan Mark Bentley , Daniel Christopher Brookings , Julien Alistair Brown , Thomas Paul Cain , Laura Jane Gleave , Alexander Heifetz , Victoria Elizabeth Jackson , Craig Johnstone , Deborah Leigh , James Madden , John Robert Porter , Matthew Duncan Selby , Zhaoning Zhu
IPC: C07D491/107 , A61K31/5377 , C07D451/02 , A61K31/506 , C07D487/04 , C07D471/08 , A61K31/5513 , A61K31/4985
CPC classification number: C07D491/107 , A61K31/4985 , A61K31/506 , A61K31/5377 , A61K31/5513 , C07D451/02 , C07D471/08 , C07D487/04
Abstract: A series of imidazo[1,2-α]pyrazine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorder; and oncological disorders.
Abstract translation: 因此，作为人TNFα活性的有效调节剂的一系列咪唑并[1,2-α]吡嗪衍生物在治疗和/或预防各种人类疾病中是有益的，包括自身免疫性和炎症性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病 和肿瘤疾病。
-
-
-
-
-
-
Search Results
27
records
(took 0.026 seconds)
